ReCode Therapeutics to Present Preclinical Data Using Proprietary SORT LNP Delivery Platform from its mRNA-based Therapeutic Programs at the ATS 2022 International Conference in San Francisco
Menlo Park, Calif. and Dallas, Texas – May 3, 2022 – ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its selective organ targeting